Canada The United States authorizes a new vaccine against Covid-19, that of Johnson & Johnson
AstraZeneca and Johnson & Johnson vaccines — where is Canada at on approvals?
The COVID-19 vaccines are among those still awaiting a green light from Health Canada, but the shots are quickly picking up steam in other parts of the world. With shortfalls in deliveries from vaccines already approved -- Moderna and Pfizer-BioNTech -- there is increasing pressure on the health agency to secure more options and get more shots into the arms of Canadians.
The United States granted this Saturday February 27 an emergency authorization to the vaccine of Johnson & Johnson against Covid-19, a news welcomed by President Joe Biden who however called not to “lower our guard” in the face of the epidemic.
This single-dose vaccine, which can be stored at refrigerator temperatures, joins those of Pfizer / BioNTech and Moderna in the massive vaccination campaign in the United States, where.
After studying in detail the data of clinical trials, conducted on more than 43,000 people, a committee of experts had recommended Friday the marketing of the vaccine of the American company.
Canada approves AstraZeneca’s COVID-19 vaccine
The approval of AstraZeneca's vaccine follows that of Pfizer and Moderna, both of which also require two doses. The AstraZeneca shot is less effective in clinical trials than its rivals' injections — 62 per cent versus high 90s — but offers distinct benefits. Read more: AstraZeneca and Johnson & Johnson vaccines — where is Canada at on approvals? One major advantage is in logistics. The shot can be stored and transported at normal refrigerated temperatures, unlike its leading mRNA-based competitors, which require ultra-cold storage.
At least three million doses of the product are ready for distribution as early as next week, according to the US government. Johnson & Johnson has committed to ship 100 million doses to the United States by the end of June."Great news"
"This is great news for all Americans, and an encouraging step in our efforts to end the crisis," said Joe Biden said in a statement.“But we cannot let our guard down or take it for granted that victory is inevitable.
With a total of 600 million doses ordered from Pfizer and Moderna, the United States will have enough vaccines by the end of July to immunize nearly the entire population. The addition of those from Johnson & Johnson could further accelerate the vaccination campaign.
COVID-19: Ontario reports 1,258 new cases; Health Canada approves AstraZeneca vaccine
What you need to know, at a glance Ontario reported 1,258 new cases of COVID-19 Friday, and 28 more deaths. There are 683 people hospitalized with COVID-19 across the province (down four in the last day), with the number of patients in ICU up by one, for a total of 284. Friday’s case total includes 52 in Ottawa, 11 in Eastern Ontario, 10 in Renfrew County and District, four in Leeds, Grenville & Lanark, and three in Hastings Prince Edward. After falling daily since mid-January, the number of active cases provincewide up for the second day, to a total of 10,294 Ontario’s science advisors say prioritizing COVID-19 vaccinations based on neighbourhood as well as age could prevent thousan
In total, more than 72 million injections have already been carried out in the country most bereaved by the pandemic in absolute terms.85.9% efficacy against severe forms
The “J&J” vaccine, injections of which have already started in South Africa, is a “viral vector” vaccine. It uses another weakly virulent virus as a carrier, transformed to add genetic instructions from part of the virus responsible for Covid-19. Once in the cells, a typical SARS-CoV-2 protein is produced, educating the immune system to recognize it.
"After rigorous analysis of the data, scientists and doctors at the FDA have determined that the vaccine meets FDA criteria for safety and efficacy for emergency clearance," the statement said in a statement. director of the agency's biological assessment and research center, Peter Marks.
If AstraZeneca isn’t widely recommended for seniors, who should get the vaccine?
While it's understandable to want more precise data, experts say what we know now doesn't mean the shot is unsafe for seniors, nor should it erode what are clear benefits.On Friday, Health Canada approved the vaccine for people over the age of 18. But, days later, the committee that advises the Government of Canada on vaccines seemed to contradict that.
In clinical trials, the vaccine's efficacy was 85.9% against severe forms of Covid-19 in the United States, according to figures released by the FDA. All regions of the clinical trial combined, it was 66.1% against moderate forms of the disease, and overall "similar" for all categories of the population (ages, ethnic groups).
The most frequently observed side effects were pain at the injection site, headache, fatigue and muscle pain.
South Africa, the worst-hit country in Africa, received a second delivery of the Johnson & Johnson vaccine on Saturday as it strives to ramp up its immunization campaign.Authorized in mid-March in Europe?
Europe, which has for its part already authorized three vaccines, AstraZeneca, Pfizer / BioNTech and Moderna, could in turn authorize the Johnson & Johnson vaccine in mid-March, "provided that the company's data on the 'efficacy, safety and quality of the vaccine are sufficiently comprehensive and convincing,' explained the European Medicines Agency in mid-February.
The European Commission has ordered 200 million doses of the vaccine from Johnson & Johnson, with an option for 200 million more. One hundred million doses must be delivered by June if the vaccine is approved.
‘Reliable scientific evidence’ needed to consider COVID-19 vaccine passports: PHAC .
The widespread use of such passports in terms of travel would be "inevitable" even should Canada choose not to implement it now, according to an expert.In a statement emailed to Global News on Sunday, Health Canada said governments and international bodies around the world are "exploring the possible use of vaccination certificates as one tool to support the re-opening of societies and economies.